APVO News and Press, Aptevo Therapeutics Inc. From 03/30/23

2023-03-30 07:47:01 ET Aptevo Therapeutics ( NASDAQ: APVO ) has raised $9.6M in non-dilutive funding, extending its cash runway beyond 12 months with an additional $50K possible based on IXINITY sales in 1Q 23. The company raised this funding by closing a transaction ...

Company Achieves Multiple Clinical and Scientific Milestones in 2022, Poised for APVO436 Phase 2 in AML 2H23, ALG.APV-527 dosing initiated 1Q23 for Solid Tumors SEATTLE, WA / ACCESSWIRE / March 30, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused ...

Completes Sale of IXINITY Deferred Payments and Portion of Milestones from Medexus to XOMA Corporation SEATTLE, WA / ACCESSWIRE / March 30, 2023 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-onc...

Trial to Evaluate Safety, Tolerability and Clinical Activity in Solid Tumors Expressing 5T4 LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / February 13, 2023 / Alligator Bioscience AB ("Alligator") (Nasdaq Stockholm: ATORX) and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced the d...

New PD-L1 x CD40 Candidate Built on Proprietary ADAPTIR™ Platform, Enters Pre-Clinical Pipeline SEATTLE, WA / ACCESSWIRE / January 9, 2023 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-...

This week will be one of the most volatile weeks of the year. It won’t matter if you’re trading penny stocks or not, the final round of major economic data and central bank meetings from the FOMC are front and center. We’ve also got another rate hike decision coming and more ...

Aptevo Therapeutics ( NASDAQ: APVO ) on Monday said it had achieved a 100% clinical benefit rate in a phase 1b trial evaluating a combination of its drug candidate APVO436 with cancer medications venetoclax and azacitidine for the treatment of patients with a type of leukemia. Shares ...

Aptevo Therapeutics Plans a Phase 2 Trial in 2H23 in Frontline and Relapsed/Refractory Patients who are Venetoclax Treatment Naïve Data Demonstrating APVO436 to be Safe and Well-Tolerated and Clinically Active Among AML Patients in Both Combination and Monotherapy Regimens Presented at ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re starting off the week with a look at the biggest pre-market stock movers for Monday! Moving stocks are upcoming meetings, clinical trial news, and more. Let’s ...

Aptevo Therapeutics press release ( NASDAQ: APVO ): Q3 GAAP EPS of -$1.50 beats by $0.14 . Aptevo had cash, cash equivalents and restricted cash of $22.6 million as of September 30, 2022. This includes $0.4 million of restricted cash that was released in October 2022. ...